Premium
Extramammary Paget’s diseases in men from the Shanghai area: its association with PSA level increase *
Author(s) -
SHI GUOHAI,
YE DINGWEI,
YAO XUDONG,
ZHANG SHILING,
DAI BO,
ZHANG HAILIANG,
SHEN YIJUN,
ZHU YAO,
ZHU YIPING,
XIAO WENJUN,
MA CHUNGUANG
Publication year - 2010
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1600-0463.2010.02657.x
Subject(s) - medicine , extramammary paget's disease , prostate cancer , incidence (geometry) , malignancy , cancer , prostate , population , confidence interval , prostate specific antigen , urology , gynecology , oncology , disease , physics , environmental health , optics
Shi G, Ye D‐W, Yao X, Zhang S, Dai B, Zhang H, Shen Y, Zhu Y, Zhu Y, Xiao W, Ma C. Extramammary Paget’s diseases in men from the Shanghai area: its association with PSA level increase. APMIS 2010; 118: 777–81. The aim of this study was to determine the incidence of prostate cancer in patients with extramammary Paget’s disease (EMPD). All cases of EMPD diagnosed between 1992 and 2007 in Shanghai Cancer Hospital were collected and analyzed for the incidence of prostate cancer. The median follow‐up was 78 months. In total, 38 cases of invasive and 10 cases of in situ EMPD had been registered. A second malignancy was found in 28.9% (11/38) of patients with invasive EMPD and in 30% (3/10) of patients with in situ EMPD. Patients had an increased risk of developing a second cancer compared with the general population (standardized incidence ratio: 1.7; 95% confidence interval 1.2–2.4). Sixteen patients had serum prostate‐specific antigen (PSA) level above 4 ng/mL; five developed prostate cancer, three of them with PSA levels beyond 100 ng/mL. The incidence of prostate cancer is 10.4% in this patient group. Patients with EMPD were more likely to have prostate cancer than the general population. Although the prognosis of EMPD is fairly good, a thorough search for a second tumor is recommended.